Adocia SA (0QAI.L)
| Previous close | 6.29 |
| Open | 6.43 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.43 - 6.43 |
| 52-week range | 2.80 - 16.16 |
| Volume | |
| Avg. volume | 3,256 |
| Market cap | 44.871M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.22 |
| Earnings date | 19 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update
LYON, France, July 24, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2024 and provides a business update.
Business WireADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets
LYON, France, July 19, 2024--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30th 2024 :
Business WireNumber of Shares and Voting Rights of ADOCIA as of June 30th, 2024
LYON, France, July 11, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions fo
